| Abstract P092 – Table 1. HTE characteristics by definition. | ||||
|---|---|---|---|---|
| HTE characteristics by definition | N (%) unless specified | HTE definition 1 total n = 865 | HTE definition 2 viremic at HTE baseline n = 435 | Suppressed at HTE baseline n = 430 |
| Patient age | 18 to 25 | 27 (3) | 15 (3) | 12 (3) |
| 26 to 50 | 383 (44) | 226 (52)a | 157 (37) | |
| >50 | 455 (53) | 194 (45) | 261 (61)a | |
| Gender | Male | 634 (73) | 305 (70) | 329 (77)b |
| Female | 164 (19) | 101 (23)b | 63 (15) | |
| Race | White | 384 (44) | 161 (37) | 161 (37) |
| Black | 402 (46) | 241 (55)a | 159 (37) | |
| Payer | Commercial | 305 (35) | 146 (34) | 159 (37) |
| Medicare | 184 (21) | 76 (17) | 108 (25)b | |
| Medicaid | 182 (21) | 118 (27)a | 64 (15) | |
| Baseline CD4 | <200 cells/mm3 | 172 (20) | 125 (29)a | 47 (11) |
| Baseline BMI | Underweight <18.5 kg/m2 | 25 (3) | 18 (4)b | 7 (2) |
| Overweight 25 to 30 kg/m2 | 284 (35) | 128 (32) | 156 (39)b | |
| Baseline eGFR (mL/min/1.73 m2) | 60 to 89 | 306 (38) | 139 (32) | 167 (43)b |
| 90+ | 409 (50) | 242 (56)a | 167 (43) | |
| Baseline ALT | > upper limit of normal (ULN) | 243 (30) | 109 (26) | 134 (35)b |
| Follow‐up (yrs) | Mean (SD) | 7.9 (4.4) | 7.9 (4.2) | 7.8 (4.6) |
| Follow‐up since HTE baseline start (mo) | Mean (SD) | 39.4 (24.2) | 34.1 (22) | 44.8 (25.2)a |
| Prior known regimens | Mean (SD) | 1.3 (1.5) | 2.1 (1.5)a | 0.5 (1.1) |
| HTE regimens | Mean (SD) | 1.9 (1.2) | 1.8 (1.2) | 2 (1.3)b |
| Duration of baseline HTE regimen (mo) | Mean (SD) | 14.5 (15.6) | 13.3 (13.5) | 15.8 (17.4)b |
| Suppressed at last available observation on baseline HTE regimen | (<200 copies/mL) | 372 (68) | 143 (49) | 229 (90)a |
| Failure at any time on baseline regimen | (2 consecutive viral loads >200 copies/mL) | 152 (18) | 115 (26)a | 37 (9) |
| Viremic on all HTE regimens | (<200 copies/mL at last observation) | 158 (26) | 132 (42)a | 26 (9) |
| First HTE regimen | Ibalizumab‐containing (IBA) | 2 (0) | 0 (0) | 2 (0) |
| Fostemsavir (FTR) | 17 (2) | 3 (1) | 14 (3)b | |
| Maraviroc (MVC) | 147 (17) | 30 (7) | 117 (27)a | |
| Etravirine (ETR) | 317 (37) | 75 (17) | 242 (56)a | |
| Enfuvirtide (ENF) | 2 (0) | 1 (0) | 1 (0) | |
| Bictegravir (BIC) | 84 (10) | 77 (18)a | 7 (2) | |
| Dolutegravir + rilpivirine (DTG + RPV) | 164 (19) | 88 (20) | 76 (18) | |
| DTG (not including DTG+RPV) | 111 (13) | 68 (16)b | 43 (10) | |
| DTG twice daily (BID) | 63 (7) | 33 (8) | 30 (7) | |
| Darunavir (DRV) | 281 (32) | 125 (29) | 156 (36)b | |
| DRV BID | 93 (11) | 32 (7) | 61 (14)b | |
| DRV+ DTG BID | 13 (2) | 9 (2) | 4 (1) | |
| With historic genotypic test | 208 (24) | 137 (31)a | 71 (17) | |
| With genotypic result available | 113 (13) | 79 (18)a | 34 (8) | |
| Resistant to ≥2 classes | 9 (8) | 5 (6) | 4 (12) | |
ap < 0.001; b0.001 ≤ p < 0.05.
p‐values are for viremic vs suppressed at baseline of HTE‐qualifying regimen.
Variable categories are limited to those with significant differences (p < 0.05).